查詢結果分析
來源資料
相關文獻
- Assessment of Cell Proliferation with Radiolabeled Pyrimidine Nucleosides and PET
- 豬瘟病毒感染後之細胞免疫反應
- 水晶體上皮細胞增殖的研究
- Fibroblasts Derived from Tissue Explants of Dilantin-Induced Gingival Hyperplasia and Idiopathic Gingival Fibromatosis Show Distinct Disparity in Proliferative Responsiveness to Epidermal Growth Factor
- 維生素C與前房液對結膜下纖維母細胞增殖所扮演的角色
- Application of MTT Colorimetric Assay to Measure Cell Proliferation and Viability for Swine Lymphocytes and Macrophages
- 生長激素與生長促進劑對豬隻生長性能與肌肉細胞體外增殖之影響
- Cytophotometric measurements of nuclear DNA content of bronchogenic carcinomas(2):The DNA ploidy and proliferative activity of bronchogenic carcinomas
- 疑似心臟移植病患服用Everolimus引起肺炎
- 精氨酸酶和細胞增殖之關係
頁籤選單縮合
題名 | Assessment of Cell Proliferation with Radiolabeled Pyrimidine Nucleosides and PET=利用放射性標幟嘧啶核苷酸及正子放射電腦斷層造影評估細胞增殖 |
---|---|
作者 | Blasberg,Ronald G.; | 書刊名 | 核子醫學雜誌 |
卷期 | 13:2 2000.06[民89.06] |
頁次 | 頁99-105 |
分類號 | 415.132 |
關鍵詞 | 細胞增殖; 正子放射電腦斷層造影; 放射性標幟嘧啶核苷酸; Tumor cell proliferation; PET imaging; Radiolabeled pyrimidine nucleosides; TdR; IUdR; |
語文 | 英文(English) |
中文摘要 | 非侵害性胞增殖造影可用以評估潛在性腫瘤生長、惡性腫瘤分級,以及鑑別腫瘤組織中最快速增生的區域,後者可以提供腫瘤空間資訊協助制定輻射治療計畫及定位切片檢查。本文比較可分解及不可分解放射性標幟嘧啶核?酸之個別優點。不可分解之嘧啶核?酸與DNA的結合效率較可分解之嘧啶核?酸為低,但由放射性代謝物及其衍生的影像解釋困難問題將會簡化。細胞增殖造影的臨床價值在於腫瘤治療效果成敗鑑別能早於以電腦斷層掃描(CT)或核磁共振造影(MR)發現的腫瘤大小或體積變化,或以正予放射電腦斷層掃描(PET)所見的葡萄糖代謝變化,這對那些療程使用細胞增殖抑制藥物治療的病人早期評估特別重要。 |
英文摘要 | Non-invasive tumor cell proliferation imaging could be used in the evaluation of tumor growth potential and grade of malignancy, and to identify the most rapidly proliferating regions of the tumor which would provide spatial information for radiation treatment planning and stereotactic biopsies. The relative merits between "degradable" and "non-degradable" radiolabeled pyrimidine analogues have been compared in this paper. Although the incorporation of nondegradable pyrimidine analogues into DNA is usually less efficient than that of the degradable pyrimidines, issues related to radiolabeled metabolites and interpretation of the images is usually simplified. The potential clinical value of cell proliferation imaging could be to identify treatment "success" or "failure" much earlier than changes in tumor size or volume identified with computed tomography (CT) or magnetic resonance imaging (MR), or changes in glucose metabolism measured with positron emission tomography (PET). This may be particularly important in the evaluation of patients early in the course of treatment, particularly those patients being treated with cytostatic drugs. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。